FindTrial
Sign In

Study of Efficacy of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small-cell Lung Cancer Before Surgery

Phase II Study of the Response Rate of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small Cell Lung Cancer Before Surgery

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00563160
Enrollment
50
Registered
2007-11-26
Start date
2005-05-31
Completion date
2007-02-28
Last updated
2010-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Neoplasms

Keywords

lung cancer

Brief summary

To study the activity of chemotherapy with Gemzar-carboplatin in the preoperative setting for operable stages of non-small-cell lung cancer and to identify novel molecular markers correlated with chemosensitivity and prognosis

Interventions

DRUGgemcitabine, carboplatin
PROCEDUREsurgery

Sponsors

Eli Lilly and Company
CollaboratorINDUSTRY
Hospital Authority, Hong Kong
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years

Inclusion criteria

* Histologically or cytologically proven, newly diagnosed primary bronchogenic non-small cell lung cancer * Measurable or evaluable tumour on chest X-ray or CT scan. * No multiple ipsilateral or contralateral parenchymal tumours * Stage I(exceptT1N0),II,IIIa disease as shown by PET-CT

Design outcomes

Primary

MeasureTime frame
pathological response rate12 months

Secondary

MeasureTime frame
progression-free survival18 months
overall survival18 months
quality of life measurements18 months

Countries

China

Contacts

Primary ContactPatricia Poon, Dr
pcm0806@netvigator.com(852) 2958 2310

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026